The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
Abstract
Overview
The combination of Simvastatin and Ezetimibe allows dual inhibition of both cholesterol
production and absorption. This treatment approach allows achieving same low serum
cholesterol levels with the administration of much lower doses of statins. This should reduce
side effects, compared to statin only therapy, enabling more patients to achieve their LDL cholesterol
treatment goals. With ezetimibe/simvastatin therapy, reductions of about 60% from
baseline in LDL cholesterol have been shown. Concomitant improvement in other lipid fractions
have also been demonstrated. The ezetimibe/simvastatin combination has been well tolerated,
with a safety profile similar to that of statin therapy. This article will review clinical experience
with ezetimibe/simvastatin combination, commenting upon its place and potential value in the
prevention of cardiovascular disease. (Heart International 2007; 3: 12-7)
Keywords
Ezetimibe, Hypercholesterolemia, Statins
Article Information
Correspondence
Dr. Savina Nodari, Associate Professor, Section of Cardiovascular Diseases, Dept. of Experimental and Applied Medicine, University of Brescia c/o Spedali Civili, P.zza Spedali Civili, 1, 25123 Brescia – Italy, nodari@med.unibs.it
Further Resources
Trending Topic
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable ...
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce ...
Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable ...
...
...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
